UK Gov. struggles as both regulator and sponsor of the pharmaceutical industry

In this age of austerity the NHS drug budget has a clear opportunity cost to add to the total of ~£12bn expenditure.  But a profitable pharmaceutical industry can contribute to economic growth and export income.
The UK government is anxious to retain and enhance our domestic science base, incentivising investment from domestic and overseas companies by using a variety of […]

Novartis on digitizing medicine in an aging world

McKinsey published an interview with Joseph Jimenez the CEO of Novartis on the theme of digitizing medicine (or is that medicines?).

Key takeaways ….biology and technology coming together as in Novartis’ work with Google on their smart contact lens … shifting from a transactional (e.g. pill as product) approach to an outcomes-based approach .

And, though it reads a bit garbled, […]

Value in Healthcare: the only “true north” for guiding decisions

In their Perspective paper ‘Why Strategy Matters Now’, Michael E. Porter and Thomas H. Lee focus on value.
In healthcare today, “Value is defined as the health outcomes achieved for patients relative to the costs of achieving them”.
“Value is created by improving the outcomes of patients” and this is done (with personalised care) over a distributed system.
“Value can be measured […]

Battles for market control in the field of generics – news from The Economist

“This week Mylan, based in the Netherlands, rejected a $40 billion bid from Teva, of Israel, arguing that it “lacks industrial logic”. To be on the safe side it has enacted a poison-pill defence against hostile takeover. Combining the world’s largest generic-drug maker, Teva, with the third-largest, Mylan, would create a company with around $30 billion in annual revenues […]

Books about the future of medicine, digital doctors, patient safety etc.

Based on my recent visit, Amazon thought I might be interested in these items. Some may be relevant to Digital Drugs…

The Digital Doctor: Hope, Hype, and Harm at the Dawn of…

Robert Wachter

The Guide to the Future of Medicine: Technology AND The Human Touch

Bertalan Meskó

The […]

Billions of pounds and the internet of things

EHealth Insider reports of Cisco and Intel reports and the more or less bright future of the Internet of Things:

Thomas Meek, 23 March 2015, IoT could generate £49b in UK healthcare, eHealth Insider,

Interestingly the starting point for generating this large business is the need to save money : ““As pressure to maintain costs in our health systems increases […]

March 23rd, 2015|Business, Value|0 Comments|

On Swiss-type claims and off-label use

Not directly connect to ‘digital drugs’ but very relevant to the understanding of off label use.

A very clear report on recent patent dispute between Warner-Lambert (part of the Pfizer group) and Actavis (a generic manufacturer):

Carpmaels & Ransford LLP (2015) International report – English courts tackle Swiss-type claims and off-label use, in : Intellectual Asset Management (IAM […]

Pfizer and Big Data To Power Patient Care

An article written by Geno Germano, Group President, Global Innovative Pharma Business, Pfizer

How Pfizer Is Using Big Data To Power Patient Care, Forbes, 2/17/2015 @ 10:18AM

February 24th, 2015|Big Data, Business|0 Comments|

On innovation, policies, economic returns – the cases of antibiotics , new and transformative drugs

In the current issue of Health Affairs :

February 2015; Volume 34, Issue 2 Biomedical Innovation

Outterson, K., J. H. Powers, G. W. Daniel and M. B. McClellan (2015). “Repairing The Broken Market For Antibiotic Innovation.” Health Affairs 34(2): 277-285.

“…Good public health practices curb inappropriate antibiotic use, making return on investment challenging in payment systems based on sales volume. We […]

on bioelectronics – ‘digital drugs’ (literally)

GSK switches to electronic medicine

“GlaxoSmithKline is betting on this new vision of medicine — curing patients through electronics instead of chemicals”
By Clive Cookson, Financial Times
Published: 15:57 August 8, 2013

“The ambition of Moncef Slaoui, GSK head of research and development, is “to have the first medicine that speaks the electrical language of our body ready for approval by the end […]

January 23rd, 2015|Business, Clinical use|0 Comments|